Efficacy and safety study of the antihistamine V00114CP 2.5 mg in the treatment of seasonal allergic rhinitis. Randomised, double-blind, three arm parellel group study including placebo and active control
Efficacy and safety study of the antihistamine V00114CP 2.5 mg in the treatment of seasonal allergic rhinitis. Randomised, double-blind, three arm parellel group study including placebo and active control
Efficacy and safety study of the antihistamine V00114CP 2.5 mg in the treatment of seasonal allergic rhinitis. Randomised, double-blind, three arm parellel group study including placebo and active control
Statut
Status :
Terminé prématurément
Type d'étude
Phase III
Age Min.
12
Ans
Age Max.
65
Ans
Genre
Tous
Aire thérapeutique :
Allergies
Maladie :
Rhinite allergique
Traitement :
L-mequitazine (Xyzall®)
Phase :
Phase III
Date de début de l'étude :
2008
End date :
19 Mai 2009
Identifiant de l'essai :
V00114 CP 305 2A
Identifiant EudraCT/CTIS :
2008-008734-36
Envoyer par email